Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF) has issued an update on its Segilola Gold Mine in Nigeria for the three months to September 30, 2022, highlighting another record quarter of production.
"This has been another record quarter of production at Segilola, beating our Q3 2022 guidance by over 1,500 ounces. We are extremely pleased with the performance of all the operational teams who have delivered this outstanding quarter during the rainy season,” Segun Lawson, Thor president and CEO said in a statement.
Arecor Therapeutics PLC (AIM:AREC) hailed the positive findings of a second phase I clinical trial of its ultra-rapid-acting insulin candidate, AT247.
Researchers found the drug had a superior pharmacokinetic (PK) profile to the gold standard treatments NovoLog and Fiasp. PK profiling reveals how a drug is absorbed, metabolised and distributed by the body.
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) is to present the results of a breakthrough anti-cancer RNA pre-clinical study today at the 29th European Society of Gene & Cell Therapy (ESGCT) in Edinburgh.
The results demonstrate for the first time that a splice-switching RNA medicine can impair Midkine action by inducing a change in the Midkine mRNA, which not only reduces full-length Midkine but also generates a non-functional shortened Midkine, Roquefort said in a statement.
Genflow Biosciences PLC (LSE:GENF) said it received a non-dilutive grant award of €250,000 for its anti-ageing research and development programme in Estonia in collaboration with IVEX, an Estonian biotech therapeutics company.
The grant was awarded by the Applied Research Programme of Enterprise Estonia, an Estonian government institution. Under the funded programme, Genflow and IVEX intend to “create precise tools to evaluate the effect of Genflow’s gene therapy drug candidates”.